7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,884.90

-146.50

-3.63%

77,325.76

+682.32

+0.89%

Crude Oil Dec 26

102.95

+0.95

+0.93%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCPK - Delayed Quote USD

Merck KGaA (MKKGY)

33.66 -0.01 (-0.03%)

At close: October 30 at 3:56:50 PM EDT

Loading Chart for MKKGY

Chart Range Bar

Interval:

In partnership with ChartIQ

Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche

Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche

Global Pooled CRISPR Screening Market Report 2026 | Capitalize on 16.1% CAGR as Thermo Fisher, Merck, Danaher and Agilent Accelerate AI-Driven Multi-Omics Workflows

Global Pooled CRISPR Screening Market Report 2026 | Capitalize on 16.1% CAGR as Thermo Fisher, Merck, Danaher and Agilent Accelerate AI-Driven Multi-Omics Workflows

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

MilliporeSigma Announces the Opening of €300 Million Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea

MilliporeSigma Announces the Opening of €300 Million Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea

Lisa Morales Joins Vinson & Elkins as NY-Based Corporate Partner

Lisa Morales Joins Vinson & Elkins as NY-Based Corporate Partner

Merck KGaA (MKKGY) Misses Q2 Earnings Estimates

Merck KGaA (MKKGY) Misses Q2 Earnings Estimates

Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade

Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade

Should Value Investors Buy Merck KGaA (MKKGY) Stock?

Should Value Investors Buy Merck KGaA (MKKGY) Stock?

Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?

Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?

Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

Company News for Jun 26, 2026

Company News for Jun 26, 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: